(19)
(11) EP 4 739 347 A1

(12)

(43) Date of publication:
13.05.2026 Bulletin 2026/20

(21) Application number: 24746885.3

(22) Date of filing: 05.07.2024
(51) International Patent Classification (IPC): 
A61K 47/68(2017.01)
A61P 35/00(2006.01)
 A61K 47/65(2017.01)
(52) Cooperative Patent Classification (CPC):
A61K 47/68037; A61K 47/65; A61K 47/6889; A61K 47/6849; A61P 35/00; A61K 47/6851
(86) International application number:
PCT/US2024/036950
(87) International publication number:
WO 2025/014830 (16.01.2025 Gazette 2025/03)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
GE KH MA MD TN

(30) Priority: 07.07.2023 US 202363512428 P
05.12.2023 US 202363606519 P
27.02.2024 US 202463558540 P
30.04.2024 US 202463640733 P
03.07.2024 US 202463667649 P

(71) Applicant: Solve Therapeutics, Inc.
San Diego, California 92121 (US)

(72) Inventors:
  • LANNUTTI, Brian
    San Diego, California 92121 (US)
  • WATKINS, Jeff
    San Diego, California 92121 (US)
  • JESSEN, Katti
    San Diego, California 92121 (US)

(74) Representative: Mewburn Ellis LLP 
Aurora Building Counterslip
Bristol BS1 6BX
Bristol BS1 6BX (GB)

   


(54) CONJUGATES OF DRUG UNITS AND TARGETING UNITS AND PRECURSOR COMPOUNDS THEREOF